+
Site Tour

Search

  • Diagnosis

    Most early-stage TR is clinically silent,1 and even with severe TR, some patients may be asymptomatic.27 In patients who become symptomatic of TR, the prevalence and severity of the symptoms are…

  • Therapy

    SWITCH TO THE interventional VIEW    For more information specific to interventional cardiology regarding PFO closure DURING THE PROCEDURE PFO closure is a minimally invasive, outpatient…

  • Guidelines

    2016 EUROPEAN SOCIETY OF CARDIOLOGY (ESC) GUIDELINES FOR THE MANAGEMENT OF ATRIAL FIBRILLATION DEVELOPED IN COLLABORATION WITH THE EUROPEAN ASSOCIATION OF CARDIOTHORACIC SURGERY (EACTS)¹ ACCESS TO…

  • Overview

    TRICUSPID REGURGITATION Tricuspid Valve Disease (TVD), including TR and tricuspid stenosis, is estimated to affect >70 million people worldwide.5 In Europe, the rate of moderate or greater TR is…

  • Overview

    Aortic Stenosis is the narrowing of the aortic orifice, typically as a result of degeneration and calcification of the valve leaflets.2 A normal aortic valve has an orifice of 3 to 4 cm.2,12…

  • Diagnosis

    The three cardinal symptoms of AS are angina, syncope or heart failure (HF).13,16 Other symptoms include dyspnea and decreased exercise tolerance.14 Primary care physicians should consider AS in…

  • Options

    The 2021 European Society of Cardiology/European Association of Cardiothoracic Surgery (ESC/EACTS) Guidelines for the management of Valvular Heart Disease (VHD) stipulate that heart valve centers…

  • Medical Management

    Depending on the symptoms, medical treatment may include digoxin, diuretics and angiotensin-converting enzyme (ACE) inhibitors (in case of HF symptoms), beta-blockers (in case of angina) and…

  • Guidelines

    Asymptomatic patients Intervention is recommended in asymptomatic patients with severe aortic stenosis and systolic LV dysfunction (LVEF <50%) without another cause (class I, B). …

  • Medical Management

    Traditional medical management of MR (both PMR and SMR) may, to an extent, relieve the symptoms of the condition, but is often insufficient at controlling the severity and progression of MR.21 ©…

You are about to leave my-connext.com

You are now leaving my-connext.com. Abbott is not responsible for any content published on the third-party website you are about to enter. Abbott has not reviewed and does not endorse any information presented on third-party websites.

The content on this website is intended for healthcare professionals in EMEA with applicable health authority product registrations, excepted those practicing in France as some of the content is not in compliance with the French Advertising law N°2011-2012 dated 29th December 2011 article 34. Click OK to confirm you are a healthcare professional to proceed.

OK Decline